A. Dallob

发表

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid

Nathan A. Yates, Keith A. Soper, Robert E. Settlage, 2015, PloS one.

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

C. Brideau, C. Chan, S. Kargman, 1996, Inflammation Research.

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

C. Hawkey, B. Gertz, N. Calder, 2001, Gastroenterology.

Involvement of hippocampal serotonergic activity in age-related changes in exploratory behavior

A. Dallob, E. Friedman, M. Brennan, 1981, Neurobiology of Aging.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias.

J. Aster, L. Silverman, W. Stock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

A. Simon, W. Potter, A. Smith, 2015, Journal of Alzheimer's disease : JAD.

MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.

B. Gertz, J. Schwartz, D. Ebel, 1997, The Journal of clinical endocrinology and metabolism.

Pharmacokinetics and pharmacodynamics of multiple oral doses of MK‐0591, a 5‐lipoxygenase—activating protein inhibitor

A. van Hecken, I. de Lepeleire, A. Porras, 1994, Clinical pharmacology and therapeutics.

The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.

N. Sadick, W. Unger, A. Dallob, 1994, The Journal of clinical endocrinology and metabolism.

Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF)-induced hyperalgesia.

A. Dallob, Y. Guindon, M. M. Goldenberg, 1987, Biochemical pharmacology.

Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration

K. Gottesdiener, A. van Hecken, I. de Lepeleire, 1999, Inflammation Research.

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors.

E. Winer, P. LoRusso, M. Kosh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced serotonin receptor activity after chronic treatment with imipramine or amitriptyline.

A. Dallob, E. Friedman, 1979, Communications in psychopharmacology.

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.

J. Waldstreicher, D. Thiboutot, L. Drake, 1999, Journal of the American Academy of Dermatology.

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.

O. Laterza, Wesley K. Tanaka, A. Dallob, 2010, Clinica chimica acta; international journal of clinical chemistry.

Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation.

E. Opas, A. Dallob, J. Humes, 1987, Biochemical pharmacology.

The effect of long-term lithium treatment on reserpine-induced supersensitivity in dopaminergic and serotonergic transmission.

A. Dallob, E. Friedman, G. Levine, 1979, Life sciences.

Regulation of phosphatidylinositol breakdown and leukotriene synthesis by endogenous prostaglandins in resident mouse peritoneal macrophages.

A. Dallob, P. Wightman, 1990, The Journal of biological chemistry.

Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor

C. Hawkey, S. Waldman, L. DeTora, 2003, Journal of clinical pharmacology.

Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model

D. Riendeau, J. Seibold, B. Gertz, 1999, Clinical pharmacology and therapeutics.

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers

B. Gertz, J. Arnout, J. Schwartz, 2000, Journal of clinical pharmacology.

Effects of chronic antidepressant treatment on serotonin receptor activity in mice.

T. Cooper, A. Dallob, E. Friedman, 1983, European journal of pharmacology.

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

W. Potter, A. Smith, G. Wilcock, 2011, Alzheimer's Research & Therapy.

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects

O. Laterza, J. Wagner, J. Schwartz, 2008, Journal of clinical pharmacology.

Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide.

R. L. Anderson, A. Dallob, S. Luell, 1988, Arzneimittel-Forschung.

L-652,343: a novel dual 5-lipoxygenase/cyclooxygenase inhibitor.

A. Dallob, J. Humes, P. Durette, 1986, Advances in prostaglandin, thromboxane, and leukotriene research.

L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor.

R. Egan, A. Ford-hutchinson, Y. Girard, 1987, Advances in prostaglandin, thromboxane, and leukotriene research.

O4-03-02 The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans

L. Ereshefsky, A. Plump, K. Gottesdiener, 2006, Alzheimer's & Dementia.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

J. Chodakewitz, W. Kraft, J. Wagner, 2010, Platelets.

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

A. van Hecken, I. de Lepeleire, P. Wong, 2000, European Journal of Clinical Pharmacology.

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Jefferson Digital

Inge, W. Kraft, J. Wagner, 2022 .

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in human

C. Hawkey, N. Calder, K. Gottesdiener, 2000 .